New "ThetaSwitch" drug may increase long-term survival in HIV disease.
D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000096:biosynthesis; D018664:Interleukin-12 / Q000096:biosynthesis; D007376:Interleukin-2 / Q000096:biosynthesis; D011070:Poly I-C / Q000008:administration & dosage / Q000627:therapeutic use*; D011072:Poly U / Q000008:administration & dosage / Q000627:therapeutic use*; D012330:RNA, Double-Stranded; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use*
D000998:Antiviral Agents; D007376:Interleukin-2; D012330:RNA, Double-Stranded; D018664:Interleukin-12; D011072:Poly U; D015215:Zidovudine; D007372:Interferons; C047490:poly(I).poly(c12,U); D011070:Poly I-C